Last reviewed · How we verify

exenatide and sitagliptin — Competitive Intelligence Brief

exenatide and sitagliptin (exenatide and sitagliptin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GLP-1 receptor agonist and DPP-4 inhibitor combination. Area: Diabetes.

marketed GLP-1 receptor agonist and DPP-4 inhibitor combination GLP-1 receptor (exenatide); DPP-4 (sitagliptin) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

exenatide and sitagliptin (exenatide and sitagliptin) — AstraZeneca. This combination drug stimulates insulin secretion through two complementary pathways: exenatide activates GLP-1 receptors to enhance glucose-dependent insulin release, while sitagliptin inhibits DPP-4 to prolong the action of endogenous GLP-1 and GIP.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
exenatide and sitagliptin TARGET exenatide and sitagliptin AstraZeneca marketed GLP-1 receptor agonist and DPP-4 inhibitor combination GLP-1 receptor (exenatide); DPP-4 (sitagliptin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (GLP-1 receptor agonist and DPP-4 inhibitor combination class)

  1. AstraZeneca · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). exenatide and sitagliptin — Competitive Intelligence Brief. https://druglandscape.com/ci/exenatide-and-sitagliptin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: